Difficulty distinguishing internal vs. external threat attribution
Periods of near-complete emotional flattening followed by intense internal agitation (self-reported)
Patient demonstrates a pattern of containment rather than resolution. Symptoms are not absent, but suppressed beneath structured behavior.
Pharmacological Management (High-Intensity Regimen)
Given the severity, chronicity, and suicide risk, patient has been initiated on an aggressive multi-axis pharmacological protocol:
Primary Antipsychotic:
Olanzapine – 20 mg/day (maximum recommended dose)
Administered 10 mg morning / 10 mg evening
Target: paranoid ideation, cognitive distortion, agitation
Secondary Antipsychotic (Augmentation):
Quetiapine – 800 mg/day (maximum recommended dose)
Administered in divided doses
Target: mood stabilization, sedation, intrusive thought dampening
Adjunct Mood Stabilization / Sedation Layer:
Valproate (Sodium Valproate) – 2000 mg/day
Serum levels monitored
Target: affective instability, impulse control
Anxiolytic (Daytime Control):
Clonazepam – 4 mg/day (upper therapeutic range)
Administered 1 mg x 4
Target: persistent anxiety, somatic tension, hypervigilance
Night Sedation Protocol (Combined):
Mirtazapine – 45 mg nightly (maximum dose)
Zolpidem – 10 mg nightly (maximum standard dose)
Promethazine – 50 mg nightly
Despite combination therapy, patient reports only partial sleep induction, indicating severity of underlying insomnia.
Clinical Interpretation of Medication Load
The patient is currently under heavy pharmacological sedation and stabilization protocol, indicative of:
Severe psychiatric burden
High relapse and self-harm risk
